Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints ...
↧
2024's biopharma winners and losers; CagriSema falls short; Merck swings China GLP-1 deal; and more
↧